Homocysteine Level and Coronary Heart Disease Incidence: A Systematic Review and Meta-analysis

November 2008
Mayo Clinic Proceedings;Nov2008, Vol. 83 Issue 11, p1203
Academic Journal
OBJECTIVE: To determine whether an elevated homocysteine level is an independent risk factor for the development of coronary heart disease (CHD) to aid the US Preventive Services Task Force in its evaluation of novel risk factors for incident CHD. METHODS: Studies of homocysteine and CHD were Identified by searching MEDLINE (1966 through March 2006). We obtained additional articles by reviewing reference lists from prior reviews, original studies, editorials, and Web sites and by consulting experts. We included prospective cohort studies that measured homocysteine and Framingham risk factors and the Incidence of CHD In the general adult population without known CHD. Each study was quality rated using criteria developed by the US Preventive Services Task Force. We conducted a meta-analysis using a random-effects model to determine summary estimates of the risk of major CHD associated with each 5-μmol/L Increase in homocysteine level. The systematic review and meta-analysls were conducted between January 25, 2005, and September 17, 2007. RESULTS: We Identified 26 articles of good or fair quality. Most studies found elevations of 20% to 50% In CHD risk for each increase of 5-μmol/L in homocysteine level. Meta-analysis yielded a combined risk ratio for coronary events of 1.18 (95% confidence interval, 1.10-1.26) for each increase of 5 μmol/L in homocysteine level. The association between homocysteine and CHD was similar when analyzed by sex, length of follow-up, outcome, study quality, and study design. CONCLUSION: Each increase of 5 μmol/L in homocysteine level increases the risk of CHD events by approximately 20%, Independently of traditional CHD risk factors.


Related Articles

  • New aspirin therapy guidelines.  // Patient Care;Apr2002, Vol. 36 Issue 6, p11 

    Deals with the recommendation of the U.S. Preventive Services Task Force (USPSTF) for physicians to discuss the benefits and risks of aspirin therapy with patients at increased risk for coronary heart disease. Factors affecting the net benefit of aspirin chemoprevention; Guidelines suggested by...

  • Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment: U.S. Preventive Services Task Force Recommendation Statement.  // Annals of Internal Medicine;10/6/2009, Vol. 151 Issue 7, p474 

    Description: New recommendation from the U.S. Preventive Services Task Force (USPSTF) on the use of nontraditional, or novel, risk factors in assessing the coronary heart disease (CHD) risk of asymptomatic persons. Methods: Systematic reviews were conducted of literature since 1996 on 9 proposed...

  • Screening Asymptomatic Adults With Resting or Exercise Electrocardiography: A Review of the Evidence for the U.S. Preventive Services Task Force. Chou, Roger; Arora, Bhaskar; Dana, Tracy; Rongwei Fu; Walker, Miranda; Humphrey, Linda // Annals of Internal Medicine;9/20/2011, Vol. 155 Issue 6, p375 

    Background: Coronary heart disease is the leading cause of death in adults. Screening for abnormalities by using resting or exercise electrocardiography (ECG) might help identify persons who would benefit from interventions to reduce cardiovascular risk. Purpose: To update the 2004 U.S....

  • What Now With Screening Electrocardiography? Lauer, Michael S. // Annals of Internal Medicine;9/20/2011, Vol. 155 Issue 6, p395 

    The author reflects on the use of screening electrocardiography. He cites the review of the U.S. Preventive Services Task Force (USPSTF) on the role of electrocardiography in screening coronary artery disease. He notes that there is no clear evidence that routine electrocardiography can improve...

  • Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment. W. LIN, KENNETH; GARCIA, SHAWN M. S. // American Family Physician;2/15/2011, Vol. 83 Issue 4, p449 

    The article describes the case of a 47-year-old man who was found to be at risk of a coronary heart disease (CHD) event in the next 10 years. The U.S Preventive Services Task Force (USPSTF) claims that the Framingham model must be used by physicians to evaluate CHD risk and suggests the use of...

  • Who should be taking aspirin? Hennekens, Charles; Manson, Joann E.; Reilly, Muredach // Patient Care for the Nurse Practitioner;Nov2002, Vol. 5 Issue 11, p1 

    The article discusses the findings of five large-scale randomized trials that evaluated the outcome of aspirin therapy for healthy individuals who are at increased risk for a first myocardial infarction. The U.S. Preventive Services Task Force found that aspirin decreases the risk of coronary...

  • Task force still says "no" to ECG screening.  // Clinical Advisor;Sep2012, Vol. 15 Issue 9, p16 

    The article reports that the US Preventive Services Task Force (USPSTF) does not approved of Electrocardiograph (ECG) screening of asymptomatic adults at low risk of a coronary heart disease (CHD).

  • Is There Benefit to Coronary Calcium Screening? Guirguis-Blake, Janelle; Lin, Kenneth W.; Barton, Mary B. // American Family Physician;4/15/2007, Vol. 75 Issue 8, p1155 

    The article comments on the benefit of coronary calcium screening. It states that cardiac computed tomography (CT) is one promising noninvasive technology for screening asymptomatic, intermediate-risk patients. The U.S. Preventive Services Task Force is developing its recommendation statement...

  • Screening for Coronary Heart Disease: Recommendation Statement.  // American Family Physician;6/15/2004, Vol. 69 Issue 12, p2891 

    Summarizes the recommendations on screening for coronary heart disease (CHD), issued by the U.S. Preventive Services Task Force. Notions about routine screening with electrocardiography; Factors associated with the risk for CHD; Diagnostic methods for CHD.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics